| **Oral triple-x (XXX) treatment compared to control for thrombophilia patients**  **Bibliography: treatment XXX versus control for patients with thrombophilia. Cochrane Database of Systematic Reviews [Year], Issue [Issue].** | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Quality assessment** | | | | | | | **Summary of findings** | | | | |
| **№ of participants (studies) Follow-up** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Publication bias** | **Overall quality of evidence** | **Study event rates (%)** | | **Relative effect (95% CI)** | **Anticipated absolute effects** | |
| **With control** | **With oral triple-x (XXX) treatment** | **Risk with control** | **Risk difference with oral triple-x (XXX) treatment** |
| **mortality (critical) (follow up: mean 12 months)** | | | | | | | | | | | |
| 2798 (5 RCTs) | serious 1 | not serious | not serious | not serious | none 2 | ⨁⨁⨁◯ MODERATE | 363/1401 (25.9%) | 346/1397 (24.8%) | **RR 0.96** (0.85 to 1.09) | **Study population** | |
| 259 per 1,000 | **10 fewer per 1,000** (39 fewer to 23 more) |
| **Low** | |
| 150 per 1,000 | **6 fewer per 1,000** (23 fewer to 14 more) |
| **High** | |
| 350 per 1,000 | **14 fewer per 1,000** (53 fewer to 32 more) |
| **myocardial infarction (critical) (follow up: mean 12 months)** | | | | | | | | | | | |
| 3182 (6 RCTs) | not serious | not serious | not serious | not serious | none | ⨁⨁⨁⨁ HIGH | 457/1618 (28.2%) | 349/1564 (22.3%) | **RR 0.88** (0.79 to 0.99) | **Study population** | |
| 282 per 1,000 | **34 fewer per 1,000** (59 fewer to 3 fewer) |
| **Low** | |
| 200 per 1,000 | **24 fewer per 1,000** (42 fewer to 2 fewer) |
| **symptomatic VTE (critical) (follow up: mean 12 months)** | | | | | | | | | | | |
| 1129 (2 RCTs) | very serious 1,3 | not serious | not serious | serious 4 | none 2 | ⨁◯◯◯ VERY LOW | 170/574 (29.6%) | 147/555 (26.5%) | **RR 0.89** (0.72 to 1.08) | **Study population** | |
| 296 per 1,000 | **33 fewer per 1,000** (83 fewer to 24 more) |
| **Low** | |
| 200 per 1,000 | **22 fewer per 1,000** (56 fewer to 16 more) |
| **High** | |
| 400 per 1,000 | **44 fewer per 1,000** (112 fewer to 32 more) |
| **stroke (critical) (follow up: mean 12 months)** | | | | | | | | | | | |
| 1723 (5 RCTs) | serious 1 | not serious | not serious | serious 5 | none 2 | ⨁⨁◯◯ LOW | 135/862 (15.7%) | 129/861 (15.0%) | **RR 0.96** (0.77 to 1.19) | 157 per 1,000 | **6 fewer per 1,000** (36 fewer to 30 more) |
| **major bleeding (critical) (follow up: mean 12 months)** | | | | | | | | | | | |
| 1010 (3 RCTs) | serious 1 | not serious | not serious | very serious 5,6 | none 2 | ⨁◯◯◯ VERY LOW | 52/505 (10.3%) | 57/505 (11.3%) | **RR 1.05** (0.74 to 1.51) | 103 per 1,000 | **5 more per 1,000** (27 fewer to 53 more) |
| **non-ulcer dyspepsia (critical) (follow up: mean 12 months)** | | | | | | | | | | | |
| 4611 (5 observational studies) | serious 7 | not serious | not serious | not serious | none 2 | ⨁◯◯◯ VERY LOW | 70/2308 (3.0%) | 118/2303 (5.1%) | **RR 1.66** (1.19 to 2.31) | 30 per 1,000 | **20 more per 1,000** (6 more to 40 more) |
| **minor bleeding (important) (follow up: mean 12 months)** | | | | | | | | | | | |
| 1204 (2 RCTs) | serious 1 | not serious 8 | not serious | serious 5 | none 2 | ⨁⨁◯◯ LOW | 40/603 (6.6%) | 96/601 (16.0%) | **RR 2.56** (1.33 to 4.92) | 66 per 1,000 | **103 more per 1,000** (22 more to 260 more) |
| **thrombosis related pain (follow up: mean 30 days; assessed with: 10-pt visual analog scale (VAS); Scale from: 0 to 10)** | | | | | | | | | | | |
| 561 (3 RCTs) | not serious | not serious 9 | not serious | serious 10 | none 2 | ⨁⨁⨁◯ MODERATE | 268 | 293 | - | The mean thrombosis related pain was **2.905** point | MD **0.4 point lower** (0.76 lower to 0.03 lower) 11 |

**CI:** Confidence interval; **RR:** Risk ratio; **MD:** Mean difference

1. ランダム割り付け、割り付けの隠蔽に深刻な限界がある（選択バイアス）
2. メタアナリシスに含められた研究は10件未満であり、出版バイアス評価のためのファンネルプロットは作成できない
3. アウトカムの評価法が不確かである
4. 信頼区間は、”効果なし”と””相当な利益”の双方を含んでいる
5. サンプルサイズがOIS（α0.05、β0.2、RRR=0.25）より少ない
6. CIが”効果なし”と”相当な害”の双方を含んでいる
7. アウトカムの測定が不確かである（上部消化管内視鏡の実施率はわずかに20%）
8. かなりの異質性があるが(I2=63%), 点推定値は同じ方向のため重要性は疑問であることから、グレードダウンとはしない
9. かなりの異質性があるが(I2=73%), 点推定値は同じ方向のため重要性は疑問であることから、グレードダウンとはしない
10. サンプルサイズは、連続アウトカムのOIS基準を満たしていない（Δ=0.2ES）
11. SMD: -0.45(-0.79～-0.12)